Merck & Co. said Friday it would discontinue developing the osteoporosis drug odanacatib and not seek regulatory approval for the treatment because it carries a higher risk of stroke. New Jersey-based Merck said it decided to stop development after an independent analysis confirmed an increased risk of stroke with use of the drug. The data…